Shares of METIS TECHBIO-P (ASX: 07666) have surged more than 5%. At the time of writing, the stock is up 5.49% to HK$11.15, with a trading turnover of HK$3.1599 million.
The catalyst for the move is the company's recent announcement of a global exclusive licensing agreement for MTS-128 with Boulevard, a company under Deerfield Management. This deal secures an upfront payment of US$20 million for METIS TECHBIO-P, with potential milestone payments reaching up to US$1.6 billion plus potential sales royalties. This transaction is reported to be the largest licensing deal for a preclinical-stage TCE (T-cell engager) project in the domestic market.
Platform and Business Model Validation
As a leading domestic AI-powered nanodelivery company, METIS TECHBIO-P's business model, which combines platform partnerships and product collaborations, has successfully gained market validation. To date, the company boasts over 30 pharmaceutical and biotechnology partners globally. Its client base primarily includes top-tier global pharmaceutical firms, innovative biotech companies, and medical research institutions.
Analyst Perspective on Milestone
Analysts have noted that the global licensing of MTS-128 marks a significant milestone for the company, signaling a shift from platform capability development to commercial realization, following the successful validation of its AiProtein platform capabilities. With the continuous generation of high-quality assets from its NanoForge and AiProtein platforms, the dual-driver model is being consistently validated. There is a positive outlook on the company's long-term value in the fields of AI-driven protein/antibody design and the development of complex therapeutic molecules.
Comments